News >

Lifirafenib Active in Melanoma, Other Solid Tumors

Jason M. Broderick @jasoncology
Published: Wednesday, Apr 08, 2020

Jayesh Desai, MD

Jayesh Desai, MD

The investigational RAF inhibitor lifirafenib (BGB-283) demonstrated antitumor activity in patients with melanoma and other solid tumors, according to findings from a phase I dose-escalation/expansion trial published in the Journal of Clinical Oncology.

thrombocytopenia and nonhematologic toxicity. The most common grade ≥3 treatment-emergent adverse events across all patients were hypertension (n = 23; 17.6%) and fatigue (n = 13; 9.9%).
Desai J, Gan H, Barrow C, et al. Phase I, open-label, dose-escalation/dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors [published online March 17, 2020]. J Clin Oncol.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication